Roche Report High Response Rate in Lung Cancer Drug Trial

barbara.lempert Roche presents updated data on investigational cancer immunotherapy MPDL3280A (anti-PDL1) in lung cancer at ECC 2013 Rapid and durable responses observed in ...

Nektar Phase II Trial for NKTR-181 Misses Primary Endpoint

mia.burns Nektar Announces Preliminary Topline Results from Phase 2 Efficacy Study for NKTR-181 in Chronic Pain Patients with Osteoarthritis of the Knee Company to Host Conference ...

Takeda Loses Second Actos Trial Over Bladder Cancer Risks

esilverman A Maryland state court jury ordered Takeda Pharmaceuticals to pay $ 1.7 million in damages for failing to properly warn a former US Army translator and his physician ...

Nektar Therapeutics shares crash on PhII pain drug trial flop

John Carroll FierceBiotech News

Infinity dumps lung cancer drug after PhII trial fails survival test

John Carroll Investigators say that the treatment failed to produce a statistically significant improvement in overall survival, forcing the biotech to wash its hands of the program ...

MorphoSys grabs $126M for clinical trial work

John Carroll The money will be used, in part, to pay for a mid-stage study of MOR208, its anti-CD19 antibody for chronic lymphocytic leukemia as well as new studies of MOR202, an anti-CD38 ...

Menopause Publishes Pivotal Trial Results for Brisdelle

barbara.lempert Menopause Publishes Pivotal Trial Results for Brisdelle™ (Paroxetine) Capsules, an FDA-Approved Non-Hormonal Therapy for Vasomotor Symptoms Associated with ...

Ariad Reaches 50 Percent Patient Enrollment in Phase 3 Epic Trial of Iclusig

barbara.lempert Interim Analysis of Efficacy in Newly Diagnosed Patients With Chronic Myeloid Leukemia Expected in Third Quarter of 2014   Cambridge, MA—September 4, 2013 – ...

At key Actos trial, lawyer claims Takeda kept cancer risks under wraps

Tracy Staton For the second time, Takeda Pharmaceuticals is trying to fend off claims that it didn't warn Actos patients about the diabetes drug's links to bladder cancer. FiercePharma ...

New UCLA Clinical Trial of MediciNova’s MN-166 in Treating Alcoholism Funded

barbara.lempert National Institute on Alcohol Abuse and Alcoholism Funds New UCLA Clinical Trial of MediciNova’s MN-166 in Treating Alcoholism                  ...

GSK Crohn’s disease Trial Misses Primary Endpoint

mia.burns ChemoCentryx Announces GlaxoSmithKline’s Release of Top-Line Results From the SHIELD-1 Phase III Study of Vercirnon MOUNTAIN VIEW, Calif., Aug. 23, 2013 (GLOBE ...

Final Patient Finishes in Prosonix Phase II Trial for COPD

mia.burns Final Patient Completes Prosonix’ Phase 2 Clinical Study with PSX1002 in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) OXFORD, England, August 16, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS